World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
109
Citations
120012
World Ranking
5642
National Ranking
3037

Overview

Michael D. Ezekowitz is affiliated with the Lankenau Institute for Medical Research in the United States. Their research primarily focuses on medicine, with a specialized emphasis on cardiology and cardiovascular medicine. Their work encompasses several subfields including internal medicine, infectious diseases, epidemiology, and molecular biology.

The scientist's main research topics are diverse but concentrated within cardiovascular health and disease management. These include atrial fibrillation management and outcomes, cardiac arrhythmias and treatments, venous thromboembolism diagnosis and management, antiplatelet therapy related to cardiovascular diseases, cardiac electrophysiology and arrhythmias, cardiac fibrosis and remodeling, and acute ischemic stroke management.

Among the recent publications authored or co-authored by Michael D. Ezekowitz are:

  • Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation, 2020, European Heart Journal
  • Drug Interactions Affecting Oral Anticoagulant Use, 2022, Circulation Arrhythmia and Electrophysiology
  • Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation, 2020, Journal of the American Heart Association
  • Effects of Rivaroxaban on Biomarkers of Coagulation and Inflammation: A Post Hoc Analysis of the X-VeRT Trial, 2020, TH Open
  • Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation, 2021, Cardiovascular Research

Frequent co-authors collaborating with Michael D. Ezekowitz include:

  • Stuart J. Connolly
  • Lars Wallentin
  • Daniel E. Singer
  • Salim Yusuf
  • Bernard J. Gersh

Michael D. Ezekowitz has published extensively in several key journals related to cardiovascular medicine. The most frequent venues include:

  • Circulation
  • European Heart Journal
  • Journal of the American Heart Association
  • The American Journal of Cardiology
  • Circulation Arrhythmia and Electrophysiology

Best Publications

  • Dabigatran versus warfarin in patients with atrial fibrillation

    Stuart J. Connolly;Michael D. Ezekowitz;John Eikelboom;Jonas Oldgren

  • 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society

    Craig T. January;L. Samuel Wann;Joseph S. Alpert;Hugh Calkins

  • Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association

    Walter N. Kernan;Bruce Ovbiagele;Henry R. Black;Dawn M. Bravata

  • 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design

    Hugh Calkins;Karl Heinz Kuck;Riccardo Cappato;Josep Brugada

  • Edoxaban versus warfarin in patients with atrial fibrillation

    Robert P. Giugliano;Christian T. Ruff;Eugene Braunwald;Sabina A. Murphy

  • Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials

    Christian T Ruff;Robert P Giugliano;Eugene Braunwald;Elaine B Hoffman

  • 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: Recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design

    Hugh Calkins;Karl Heinz Kuck;Riccardo Cappato;Josep Brugada

  • Forecasting the Future of Cardiovascular Disease in the United States A Policy Statement From the American Heart Association

    Paul A. Heidenreich;Justin G. Trogdon;Olga A. Khavjou;Javed Butler

  • Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.

    Gregory G. Schwartz;Anders G. Olsson;Michael D. Ezekowitz;Peter Ganz

  • 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society

    Craig T. January;L. Samuel Wann;Hugh Calkins;Lin Y. Chen

  • 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons

    Craig T. January;L. Samuel Wann;Hugh Calkins;Lin Y. Chen

  • 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary

    Craig T. January;L. Samuel Wann;Joseph S. Alpert

  • Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators.

    Michael D. Ezekowitz;Samuel L. Bridgers;Kenneth E. James;Nathan H. Carliner

  • Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial

    John W. Eikelboom;Lars Wallentin;Stuart J. Connolly;Mike Ezekowitz

  • Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: An analysis of the RE-LY trial

    Lars Wallentin;Salim Yusuf;Michael D Ezekowitz;Marco Alings

  • 2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline) A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

    L. Samuel Wann;Anne B. Curtis;Kenneth A. Ellenbogen;N.A. Mark Estes

  • 2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

    Valentin Fuster;Lars E. Rydén;Davis S. Cannom;Harry J. Crijns

  • The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).

    Paul A. Reilly;Thorsten Lehr;Sebastian Haertter;Stuart J. Connolly

  • Newly identified events in the RE-LY trial.

    Stuart J. Connolly;Michael D. Ezekowitz;Salim Yusuf;Paul A. Reilly

  • Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. the miracl study: a randomized controlled trial

    G.G Schwartz;A.G Olsson;M.D Ezekowitzet al

Frequent Co-Authors

Stuart J. Connolly
Stuart J. Connolly McMaster University
Lars Wallentin
Lars Wallentin Uppsala University
Salim Yusuf
Salim Yusuf McMaster University
John W. Eikelboom
John W. Eikelboom Population Health Research Institute
Agneta Siegbahn
Agneta Siegbahn Uppsala University
Jonathan P. Piccini
Jonathan P. Piccini Duke University
Daniel E. Singer
Daniel E. Singer Harvard University
Kenneth W. Mahaffey
Kenneth W. Mahaffey Stanford University
Gregg C. Fonarow
Gregg C. Fonarow University of California, Los Angeles
Bernard J. Gersh
Bernard J. Gersh Mayo Clinic

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Choosing a career in medicine doesn’t always mean pursuing a traditional MD. There are a wide range of online degrees and alternative paths available for those interested in the healthcare sector. For example, direct entry nursing programs can offer accelerated routes for students with a bachelor’s degree in another field, allowing them to kick-start a nursing career in less time.

If you’re interested in office-based medical careers, consider schools specializing in medical billing and coding schools with financial aid. These programs can lead to in-demand roles without extensive upfront costs, making them attractive for many working adults.

Not all nursing programs have rigid entrance exam requirements. You can explore do all nursing schools require the teas to find nursing schools that waive the TEAS or HESI, opening opportunities for more students.

For those interested in leadership and management roles, an healthcare administration associate degree online provides flexible options for building foundational knowledge and advancing in the ever-evolving healthcare industry.

Best Scientists Citing Michael D. Ezekowitz

Trending Scientists